

targovax

***Arming the patient's immune
system to fight cancer***

Q3 2015

Important notice and disclaimer

- This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.
- There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the company's ability to successfully commercialize and gain market acceptance for Targovax's products; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.

Targovax – “Arming the patient’s immune system to fight cancer”

1

A Nordic immuno-oncology leader

- ✓ Oncolytic adenoviruses targeted at all solid, injectable tumors
- ✓ RAS-mutated peptide immunotherapy, targeted at all RAS-mutated cancers



2

Unique portfolio with promising data

- ✓ TG01 is the only RAS-specific cancer vaccine in development
- ✓ ONCOS-102 is the only oncolytic virus which has shown tumor-specific T-cell activation

ONCOS

TG

3

Multiple value inflection points

- ✓ Multiple shots on goal through programs in 6 indications
- ✓ 9 clinical read-outs over next 2 years



4

Experienced management team

- ✓ A highly experienced international management team
- ✓ Strong and recently strengthened board




5

Backed by leading life science investors

- ✓ Private placement of NOKm 200 (USDm 25) in June 2015
- ✓ HealthCap is the largest owner with 31.6 %
- ✓ IPO planned for 2016

HealthCap


Financial highlights Q3 2015 – Strengthened capital position



- Gross proceeds from the private placement in June were NOKm 200
- IPO planned for 2016
- Current cash with current cash lasts until 2H16
- Flexibility to extend runway

Financial highlights Q3 2015 – Increased expenditures in line with plan

Operating expenses (NOKm)



Q3 2015 has been a transformational quarter for Targovax (I/II)


June 2015	Today
Technology	
<i>One technology</i>	<i>Two promising technologies</i>
Studies	
<i>2 small Phase I studies</i>	<i>Late stage planning of 5 Phase I/II combination studies</i>
Investor base	
<i>Limited</i>	<i>3x investor base</i>
Organization	
<i>Small</i>	<i>Highly experienced international organization</i>
Visibility	
<i>Unknown</i>	<i>Increased visibility and international press coverage</i>
Collaborations	
<i>None</i>	<i>2 scientific collaborations signed</i>

Q3 2015 has been a transformational quarter for Targovax (I/II)


- ✓ Completed merger with Oncos Therapeutics which formed a Nordic immuno-oncology powerhouse
- ✓ Successful NOKm 200 private placement completed
- ✓ TG01 Pancreatic cancer Phase II study and ONCOS-102 Mesothelioma Phase II study are progressing as planned
- ✓ Signed agreement with Ludwig Cancer Research (LICR) and the Cancer Research Institute (CRI) to evaluate ONCOS-102 in combination with other immunotherapies
- ✓ Entered into collaboration with Czech biotech company Sotio to study the combination of ONCOS-102 and Sotio's dendritic cell therapy

Targovax focus on: Solid tumors susceptible to immunotherapy and those with RAS mutations

Solid tumors



RAS mutations








¹ Patients were preselected by Merck PD-L1 IHC assay

² 11% in PD-L1 (Roche) negative: 43% in PD-L1 + population

³ Cancer Res, PS 2012, Nov 15, 2012

Cancer immunotherapies are combined to maximize efficacy

Immuno-oncology mechanisms	Wake up the immune system	Teach the T-cells at the lymph nodes	Attack the cancer with T-cells systemically	Disarm cancer's defence
 <i>Car analogy</i>	<i>Ignite the engine</i>	<i>Switch on the GPS–targeting</i>	<i>Press on the gas pedal</i>	<i>Release the brakes</i>
 Peptide vaccines/ GM-CSF	✓	✓	✓	
 Viral vaccines	✓	✓	✓	
 Peptide loaded viral vaccine T-Cell therapy	✓	✓	✓	
 Check point inhibitors ("CPI"s)				✓

Source: Company websites, press releases and filings

An emerging immuno-oncology specialist with two platform technologies


	ONCOS	TG
1 Nature of therapy	<ul style="list-style-type: none"> ✓ Adenovirus vaccines creating immunity against patient's own antigens 	<ul style="list-style-type: none"> ✓ RAS-targeting peptide cocktails
2 Mode of Action	<ul style="list-style-type: none"> ✓ The virus makes the tumors release tumor antigens 	<ul style="list-style-type: none"> ✓ The RAS peptides are picked up by dendritic cells
3 Efficacy	<ul style="list-style-type: none"> ✓ 40% of evaluable patients showed stable disease 	<ul style="list-style-type: none"> ✓ 93%-100% patients with immune response in resected pancreatic cancer and 56% in advanced disease
4 Practicality	<ul style="list-style-type: none"> ✓ Intratumoral injections ✓ State-of-the-art manufacturing ✓ Low cost of goods 	<ul style="list-style-type: none"> ✓ Intradermal injections of standardized dose ✓ State-of-the-art manufacturing ✓ Low cost of goods
5 Opportunities	<ul style="list-style-type: none"> ✓ A perfect match with CPIs ✓ May also be combined with other SoC treatment modalities 	<ul style="list-style-type: none"> ✓ RAS mutations represent a unique target ✓ Solid scientific rationale for combining TG01 e.g. CPIs

Targovax has differentiated assets with orphan indications*


	Indication(s)	Program	Discovery	Pre-clinical	Phase I	Phase II	Phase III
Development	Pancreas cancer*	TG01					
	Mesothelioma*	ONCOS-102					
	Melanoma	ONCOS-102					
	Colorectal cancer	TG02					
Exploratory	Ovarian cancer*	ONCOS-102					
	Prostate cancer	ONCOS-102					
Discovery	Discovery	TG03					
		ONCOS-402					
		ONCOS-802					
		ONCOS-902					

- Targovax has a broad and diversified pipeline with several promising compounds targeting multiple indications
- There is a low price tag of advancing the compounds to a go/no-go decision for the specific indications

Current view of the clinical development program 2015 – 2018



Expected news flow 2016 – 2018 shows multiple value inflection points



Unique immuno-oncology portfolio with promising data

1

Immuno-oncology is the fastest growing life science segment

2

Unique portfolio with promising data

3

Multiple value inflection points

4

Experienced management team

5

Backed by leading life science investors



Appendix

Internationally experienced senior management team



Gunnar Gårdemyr, CEO

- More than 30 years of international experience from the pharmaceutical and biotech industry including business development, mergers & acquisitions, global marketing and commercial strategy



Øystein Soug, CFO

- Previously CFO at Algeta, where he built up the functions of Finance, IR, Compliance, IT and HR, and oversaw its ultimate sale to Bayer for USDbn 2.9



Dr. Magnus Jaderberg, CMO

- More than 25 years in various R&D functions and previously CMO at Bristol Meyers Squibb (Europe)



Jon Amund Eriksen, COO

- Co-Founder of Targovax, with more than 35 years of R&D experience from pharmaceutical and biotech industry, 25 years within immuno-oncology



Antti Vuolanto, Executive VP

- Co-Founder of Oncos Therapeutics, with more than 10 years of experience in biotechnology business development, product development and commercialization



Tina Madsen, VP, Quality Assurance

- More than 20 years of experience within Research & Development and commercial manufacturing in the pharmaceutical and biotech industry, including quality assurance, process development and formulation



Nikolaj Knudtzon, Head of HR

- More than 15 years of experience within development and implementation of strategic HR in close cooperation with business and executives



Peter Skorpil, VP, Business Development

- Extensive experience in licensing, commercial assessments, business intelligence and partnering and previously Commercial Director at Pronova BioPharma

Experienced Board of Directors



Jónas Einarsson, MD

- Chief Executive Officer of the Radiumhospitalets Forskningsstiftelse
- On the board of several Norwegian Biotech companies, and was one of the initiators behind Oslo Cancer Cluster and the Oslo Cancer Cluster Innovation



Johan Christenson, MD, PhD

- Partner of HealthCap
- Previously supervised the healthcare portfolio of SEB Företagsinvest
- Senior management experience from Astra Pain Control and AstraZeneca
- PhD in basic neuroscience
- Author of 17 scientific articles



Per Samuelsson

- Partner of HealthCap
- Prior to joining HealthCap in 2000, he gained over 15 years of investment banking experience, mainly with Aros Securities in Sweden
- Prior to this Mr. Samuelsson was head of Research, also at Aros Securities



Eva-Lotta Allan

- Currently Chief Business Officer at Immunocore
- More than 25 years of experience from the biotechnology and life science industry in both private and public companies
- Has held senior positions at e.g. Ablynx, Vertex Pharmaceuticals and Oxford Asymmetry (Evotec)



Lars Lund-Roland

- CEO of Bringwell AB
- Previously MD of MSD Norway (Merck & Co Inc. subsidiary) and has more than twenty-five years' experience from various executive positions within marketing and sales
- Chairman of the Board of PI Innovation and has served as board member of Infodoc and Health Tech



Bente-Lill Romøren

- Board member of Radiumhospitalets Forskningsstiftelse, Nordic Nanovector, and chairman of Farmastat and Photocure
- Was previously employed by Novo Nordisk Scandinavia AS from 1976 to 2012 in various positions, including as CEO of the Norwegian unit (2008-2012)



Robert Burns, PhD

- CEO at 4-Antibody and Chairman at Haemostatix
- Extensive experience in building biotechnology companies, previously CEO of Affitech and Celldex Therapeutics
- Prior to Celldex, Robert was Director of Technology Licensing at the Ludwig Institute for Cancer Research



Diane Mellett

- A consultant to biotech and medical device companies
- Qualified in both UK and US law
- Formerly General Counsel for Cambridge Antibody Technology (CAT)
- Led successful defence for CAT concerning a contractual dispute on Humira®

Strong shareholder base comprising several reputable institutional investors

Shareholder structure 30 September 2015

Shareholder	No. of shares	Ownership
HealthCap	8,490,918	31.6%
Radiumhospitalets Forskningsstiftelse	3,410,589	12.7%
Trojan AS	2,462,000	9.2%
Arctic Funds Plc	907,000	3.4%
Timmuno AS	724,650	2.7%
Prieta AS	720,000	2.7%
Portia AS	640,000	2.4%
Danske Bank A/S (Nominee)	587,971	2.2%
Nordnet Bank AB (Nominee)	569,522	2.1%
KLP Aksje Norge VPF	460,000	1.7%
Eltek Holding AS	442,000	1.6%
Statoil Pensjon	436,000	1.6%
Storebrand Vekst	425,000	1.6%
Pactum AS	400,000	1.5%
Birk Venture AS	386,680	1.4%
Op-Europe Equity Fund	357,869	1.3%
Trygve Schiørbecks Eff. AS	286,449	1.1%
Viola AS	280,000	1.0%
Kommunal Landspensjonskasse	270,000	1.0%
DNB Grønt Norden	250,919	0.9%
20 largest shareholders	22,507,567	83.8%
Other shareholders (~160)	4,351,241	16.2%
Total shareholders	26,858,808	100.0%

- 26,858,808 ordinary shares
- Option dilution < 9%
- Approx. ~180 shareholders
- Average strike price on options NOK 23.5
- Total dilutive effect of options is <9.0%

Q3 2015 – Financial summary

NOK thousands	Q3 2015	Q3 2014	9M 2015	9M 2014	FY 2014
Total operating revenues	144	0	144	52	72
Total operating expenses	-29,478	-4,115	-48,997	-9,361	-17,642
Operating profit/loss	-29,333	-4,115	-48,853	-9,310	-17,570
Net financial items	487	1	500	-85	-77
Income tax	-43	0	-43	0	0
Net profit/loss	-28,889	-4,114	-48,396	-9,395	-17,646
Basic and diluted EPS (NOK/share)	-1.08	-0.44	-3.18	-1.33	-2.50
Net increase/decrease in cash and cash equivalents	162,228	-3,232	144,141	60,639	54,182
Cash and cash equivalents at beginning of period	44,465	72,241	62,552	8,370	8,370
Cash and cash equivalents at end of period	206,694	69,009	206,694	69,009	62,552

Thank you for your attention